Fisher Cynthia E, Hohl Tobias M, Fan Wenhong, Storer Barry E, Levine David M, Zhao Lu Ping, Martin Paul J, Warren Edus H, Boeckh Michael, Hansen John A
Department of Medicine, University of Washington, Seattle, WA.
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Blood. 2017 May 11;129(19):2693-2701. doi: 10.1182/blood-2016-10-743294. Epub 2017 Mar 7.
Invasive aspergillosis (IA) is a significant cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT). Previous studies have reported an association between IA development and single nucleotide polymorphisms (SNPs), but many SNPs have not been replicated in a separate cohort. The presence of a positive serum galactomannan assay (SGM+) has also been associated with a worse prognosis in patients with IA, and genetic determinants in this subset of patients have not been systematically studied. The study cohort included 2609 HCT recipients and their donor pairs: 483 with proven/probable IA (183 SGM+) and 2126 with no IA by standard criteria. Of 25 SNPs previously published, we analyzed 20 in 14 genes that passed quality control. Samples were genotyped via microarray, and SNPs that could not be genotyped were imputed. The primary aim was to replicate SNPs associated with proven/probable IA at 2 years; secondary goals were to explore the associations using an end point of SGM+ IA or proven/probable IA using a different genetic model or time to IA (3 months vs 2 years) compared with the original study. Two SNPs in 2 genes (, ) were replicated. Thirteen SNPs in 9 genes had an association at ≤ .05 using the secondary aims (, , , , , , , , ), with hazard ratios ranging from 1.2 to 3.29. Underlying genetic differences can influence development of IA following HCT. Identification of genetic predispositions to IA could have important implications in donor screening, risk stratification of recipients, monitoring, and prophylaxis.
侵袭性曲霉病(IA)是异基因造血细胞移植(HCT)后发病和死亡的重要原因。先前的研究报道了IA发生与单核苷酸多态性(SNP)之间的关联,但许多SNP尚未在另一队列中得到验证。血清半乳甘露聚糖检测呈阳性(SGM+)也与IA患者的不良预后相关,而这部分患者的遗传决定因素尚未得到系统研究。研究队列包括2609名HCT受者及其供者对:483例确诊/疑似IA患者(183例SGM+)和2126例按标准标准无IA的患者。在先前公布的25个SNP中,我们分析了14个基因中的20个通过质量控制的SNP。样本通过微阵列进行基因分型,无法进行基因分型的SNP进行推算。主要目的是验证与2年时确诊/疑似IA相关的SNP;次要目标是使用SGM+ IA或确诊/疑似IA的终点,采用不同的遗传模型或与原始研究相比的IA发生时间(3个月与2年)来探索关联。2个基因中的2个SNP得到了验证。9个基因中的13个SNP在次要目标分析中(,,,,,,,,)在≤0.05时有相关性,风险比范围为1.2至3.29。潜在的遗传差异可影响HCT后IA的发生。识别IA的遗传易感性可能对供者筛选、受者风险分层、监测和预防具有重要意义。